Use of erythropoietin before the initiation of dialysis and its impact on mortality - PubMed (original) (raw)
Use of erythropoietin before the initiation of dialysis and its impact on mortality
J Fink et al. Am J Kidney Dis. 2001 Feb.
Abstract
Erythropoietin (EPO) is recommended in individuals progressing toward end-stage renal disease (ESRD) to correct anemia and its complications, which are common in this disease. This study evaluated the impact of EPO administered before dialysis on mortality in incident ESRD patients. A total of 4,866 patients whose exposure to pre-ESRD EPO was determined from Health Care Financing Administration 2728 forms were analyzed. The median follow-up was 26.2 months, with 1,107 (22.7%) patients given EPO and 1,892 (38.9%) deaths. EPO use was more common in patients who had insurance before dialysis, remained employed, were started on renal replacement therapy outside the hospital, or initiated on peritoneal dialysis, which could be indicative of early intervention or quality care. The risk of death after starting dialysis was lower for patients treated with EPO before dialysis compared with patients who were not treated (adjusted relative risk 0.80, 95% confidence interval 0.70 to 0.91). There was no direct relationship between predialysis hematocrit and mortality; however, the most significant survival benefit with EPO use was in patients with the highest hematocrit values (adjusted relative risk 0.67, 95% confidence interval, 0.51 to 0.89). The most significant effect of pre-ESRD EPO use was observed during the first 19 months after starting dialysis (adjusted relative risk, 0.81; 95% confidence interval, 0.71 to 0.91), but this benefit diminished in patients with longer follow-up on renal replacement therapy. Use of EPO before dialysis confers a survival benefit to ESRD patients, especially in patients with an adequate hematocrit response before initiation of dialysis.
Similar articles
- Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time.
Lu WX, Jones-Burton C, Zhan M, Salzberg DJ, Moore J Jr, Fink JC. Lu WX, et al. Nephron Clin Pract. 2005;101(2):c79-86. doi: 10.1159/000086226. Epub 2005 Jun 20. Nephron Clin Pract. 2005. PMID: 15976508 - Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
Moreno F, Aracil FJ, Pérez R, Valderrábano F. Moreno F, et al. Am J Kidney Dis. 1996 Apr;27(4):548-56. doi: 10.1016/s0272-6386(96)90166-3. Am J Kidney Dis. 1996. PMID: 8678066 Clinical Trial. - Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States.
Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Obrador GT, et al. J Am Soc Nephrol. 1999 Aug;10(8):1793-800. doi: 10.1681/ASN.V1081793. J Am Soc Nephrol. 1999. PMID: 10446948 - [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
Dimković N. Dimković N. Med Pregl. 2001 May-Jun;54(5-6):235-40. Med Pregl. 2001. PMID: 11759218 Review. Croatian. - Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
Collins AJ. Collins AJ. Nephrol Dial Transplant. 2003 Jun;18 Suppl 2:ii2-6. Nephrol Dial Transplant. 2003. PMID: 12819293 Review.
Cited by
- Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin-a post-hoc analysis of the UTOPIA study.
Katakami N, Mita T, Sato Y, Watada H, Shimomura I. Katakami N, et al. Diabetol Int. 2024 Feb 10;15(3):379-388. doi: 10.1007/s13340-024-00693-x. eCollection 2024 Jul. Diabetol Int. 2024. PMID: 39101158 - Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.
Miura T, Sato T, Yano T, Takaguri A, Miki T, Tohse N, Nishizawa K. Miura T, et al. Cardiovasc Drugs Ther. 2023 Dec;37(6):1175-1192. doi: 10.1007/s10557-022-07321-3. Epub 2022 Feb 12. Cardiovasc Drugs Ther. 2023. PMID: 35150385 Review. - Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study.
Xu Y, Evans M, Barany P, James G, Sjölander A, Carrero JJ. Xu Y, et al. Clin Kidney J. 2021 Feb 5;14(7):1780-1788. doi: 10.1093/ckj/sfaa213. eCollection 2021 Jul. Clin Kidney J. 2021. PMID: 34221385 Free PMC article. - Risk Score to Predict 1-Year Mortality after Haemodialysis Initiation in Patients with Stage 5 Chronic Kidney Disease under Predialysis Nephrology Care.
Doi T, Yamamoto S, Morinaga T, Sada KE, Kurita N, Onishi Y. Doi T, et al. PLoS One. 2015 Jun 9;10(6):e0129180. doi: 10.1371/journal.pone.0129180. eCollection 2015. PLoS One. 2015. PMID: 26057129 Free PMC article. - Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia.
Duman N, Uyanik A, Unsal A, Sezer S, Camsari T, Cirit M, Yilmaz ME, Altun B, Duranay M, Yildiz A, Sahin I, Dogukan A, Ustundag S, Karayaylali I, Kahveci A, Sindel S, Kiykim AA, Yenicerioglu Y, Akbas E, Ozdener F. Duman N, et al. Clin Kidney J. 2014 Oct;7(5):464-9. doi: 10.1093/ckj/sfu079. Epub 2014 Jul 29. Clin Kidney J. 2014. PMID: 25504109 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials